All news

WIPR 2013 is an international event designed to make the link between research and industry in the field of personalized radio immunotherapy. Co-organized by Subatech, the Nantes “Ecole des Mines”, the Nantes-Angers Cancer Research Center (CRCNA), Arronax, Atlanpole Biotherapies and the Cancéropôle Grand Ouest, WIPR 2013 will be held in Nantes from 9th to 12th July 2013 at the new Faculty of Pharmacy of Nantes.

IMODI research project certified by Atlanpole Biotherapies receives € 13.4 million in the framework of “investments for the future ”. IMODI aims to facilitate the selection of new and effective treatments against eight types of cancer. Biofortis, a member of the cluster, is one of the six project partners industrial groups. Below is a focus on its role and on the benefits of such a project for its development.

The GelTOP collaborative project certified by Atlanpole Biotherapies in 2007 aims to develop hydrogels for in situ release of active ingredients in difficult situations such as bone tumors or unconsolidated fractures and thus allow bone reconstruction. Between 2009 to 2013, Biomatlante, the project leader, has joined forces with two partners to meet this objective: Inserm and another company which is also a member of the cluster i.e. Atlantic Bone Screen.

[Presse release] ATLAB Pharma SAS made a presentation at AACR 2013 (Washington DC, USA, April 6-10, 2013) of an updated combined analysis of 4 Phase I and Phase II studies involving 114 patients treated with ATL101 demonstrating that PSMA imaging might be used to predict response to ATL101 radioimmunotherapy.

[Presse release] In-Cell-Art, a biotechnology company specializing in nanocarrier technologies called Nanotaxi® for macromolecules delivery (DNA, RNA, Protein), announces the joint research program with one of the top 10 global pharmas to validate targets for the development of antibodies with potential therapeutic use in human by ICANtibodies, a fully integrated antibodies discovery process without peptide and recombinant protein (from plasmid DNA antigen design and synthesis, Nanotaxi®/plasmid formulation and immunization in various species, to antibody quality controls). The figure below is the process of ICANtibodies. The financial terms of this agreement are not disclosed.

[Press release] HEMARINA, the French based Biotechnology Company, today announced its establishment in Boston, Massachusetts USA thru the incorporation of Hemarina Inc. on March 15th, 2013. The new affiliate will be in charge of North and South America and will allow HEMARINA to deploy its global strategy more efficiently, and will be the corporate link between its headquarters located in Morlaix, France to facilitate its partnerships in the Americas.

On March 26th, the network companies and laboratories were invited to an information meeting on the European regulations for medical devices. The meeting was co-organized by Entreprise Europe Ouest, the Pays de la Loire Chamber of Commerce and Industry, Atlanpole Biotherapies, the Pays de la Loire Regional Agency, CAP'TRONIC and the Britain Health Regional Center for Innovation and Technology Transfer (CRITT).

Initiated in 2010, European Interreg project comprises 5 clusters and combines 250 SMEs specializing in biomaterials. The objective is to set up a support network for innovation in the field of "Biomaterials" in Northwest Europe (NWE area). Spread over 46 months, the project has already enabled the implementation of tools and other concrete results.

The European Commission has just launched the Health FP7 call for proposals. The first deadline to note is September 25, 2012.